Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma

ZURICH, July 22, 2026 /PRNewswire/ -- Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the...